4-Methyl-α-methyltryptamine

4-Me-αMT
Clinical data
Other names4-Me-αMT; 4-Me-AMT; 4-Methyl-αMT; 4-Methyl-AMT; 4,α-Dimethyltryptamine; 4,α-DMT; MP-809; MP809; Methyl-2-methyltryptamine
Routes of
administration
Oral
Drug classAntidepressant
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-methyl-2-(4-methyl-1H-indol-3-yl)-ethylamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16N2
Molar mass188.274 g·mol−1
3D model (JSmol)
  • CC(N)Cc2c1c([nH]c2)cccc1C
  • InChI=1S/C12H16N2/c1-8-4-3-5-11-12(8)10(7-14-11)6-9(2)13/h3-5,7,9,14H,6,13H2,1-2H3 checkY
  • Key:KEOYEGHPRBDSKD-UHFFFAOYSA-N checkY
  (verify)

4-Me-αMT (developmental code name MP-809), or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine (4,α-DMT), is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET).

Use and effects

4-Me-αMT is active at a dose of 20 to 60 mg orally in humans, though described as being an antidepressant rather than a hallucinogen. It was found to be effective as an antidepressant in preliminary clinical studies. Alexander Shulgin has said that 4-Me-αMT produced some feelings of unreality at 20 mg, as well as skin flushing, muscle tightness, and mydriasis. However, he has said that it could not be called a hallucinogen at assessed doses and has listed the hallucinogenic dose as being greater than 60 mg.

Interactions

Pharmacology

Pharmacodynamics

4-Me-αMT partially reverses reserpine-induced behavioral depression in rodents (by up to 60%), but does not produce hyperlocomotion. This was the case at a dose of 50 mg/kg, whereas αMT produced clear hyperlocomotion and near-fully reversed reserpine-induced hypoactivity (by 95%) at a dose of 15 mg/kg. Hence, 4-Me-αMT shows reduced antidepressant- and psychostimulant-like potency compared to αMT. It is also less active than αET. The drug is said to have very weak monoamine oxidase inhibition.

Chemistry

Analogues

Analogues of 4-methyl-AMT include α-methyltryptamine (AMT), 4-methyl-AET, 4-methyl-DMT, 4-HO-AMT, 4-HO-AET, and RS134-49 (4-methyl-THPI), among others.

History

4-Me-αMT was first described in the scientific literature by 1962. It was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never marketed.

See also